

Ole Morten Seternes
Job description
Ole Morten Seternes is a professor of Pharmacology and leads the Cell Signaling and Targeted Therapy Research Group at the Department of Pharmacy. His research interests focus on basic research into the mechanisms of cellular signaling, with a particular focus on kinases and phosphatases involved in the regulation of mitogen-activated kinase signalling pathways.
Biography
Ole Morten Seternes received all of his academic education from the University of Tromsø, now known as UiT The Arctic University of Norway. He obtained his Cand Scient degree (equivalent to a Master's degree) in 1992 from the Virology Research Group at the Department of Medical Biology, with Professor Terje Traavik as his supervisor. His Dr.scient degree (equivalent to a PhD degree) was obtained from the same department at the Medical Genetics Research Group in 1998, with a thesis entitled "The immediately early gene c-fos and the cAMP response element binding protein CREB: studies of transcriptional activity regulated by different signaling pathways," under the supervision of Professor Ugo Moens.
From 1998-2001, he was granted a personal postdoctoral fellowship from the Norwegian Research Council to work in the ICRF (now Cancer Research UK) Stress Response Laboratory under the direction of Professor Steve Keyse at the University of Dundee in Dundee, Scotland, UK. After returning from the UK, he received a career development fellowship from the Norwegian Research Council to start his own research group at the Department of Medical Biology, University of Tromsø.
In 2006, he became a senior research fellow of the Norwegian Cancer Society and was appointed as a full professor in Pharmacology and leader of the Cell Signaling and Targeted Therapy Research Group at the Department of Pharmacy in 2010.
Error rendering component
Research interests
The focus of the research is on basic cellular signaling, with a particular interest in the role of protein kinases and phosphatases in regulating MAP kinase signaling in human cancer. This includes the study of classical MAP kinases, such as p38 MAPK (MAPK14), as well as atypical MAPK kinases, such as ERK3 (MAPK6) and ERK4 (MAPK4). Additionally, the research examines negative regulators of MAP kinases, such as the family of MAP kinase phosphatases.
Teaching
Teach in the courses:
FAR2206 and FAR2207